Evidence of TAM-stimulated growth in breast tumors and biopsies
| TAM Withdrawal Responses | |||||
|---|---|---|---|---|---|
| Patients | Worse than PR5-a | PR | CR | PR + CR/Duration (Range) | Citation |
| Advanced disease | 19 /19 | 0 /19 | 0 /19 | 0% | Beex et al., 1981 |
| Postmenopausal with metastatic disease5-b | 6 /9 | 1 /9 | 2 /9 | 22%/10–14 months | Rudolph, 1986 |
| Postmenopausal with metastatic disease | 84 /87 | 3 /87 | 0 /87 | 3%/9–10.3 months | Taylor et al., 1986 |
| Postmenopausal | 56 /615-c | 4 /61 | 1 /61 | 8%/3–10 months | Canney et al., 1989 |
| Advanced disease | 60 /65 | 5 /65 | 0 /65 | 8%/3–40 months | Howell et al., 1992 |
| Mean (PR+CR) | 225 /241 | 13 /241 | 3 /241 | 6.6% | |
| Overall (PR+CR+DS) | 19.5% (47/241)5-d | ||||
| TAM Stimulation of Primary Breast Tumors In Vitro5-e | ||
|---|---|---|
| ER Status | Response | n (%) |
| ER-positive | TAM-stimulated | 11/153 (7) |
| ER-negative | TAM-stimulated | 1/71 (1.4) |
| ER-positive | Estradiol-stimulated | 47/153 (31) |
| ER-negative | Estradiol-stimulated | 10/71 (14) |
| ER-positive | TAM-stimulated and estradiol-stimulated | 6/153 (4) |
| ER-negative | TAM-stimulated and estradiol-stimulated | 0/71 (0) |
↵5-a PR, partial response; CR, complete response.
↵5-b All patients were selected on the basis of having experienced a response to TAM.
↵5-c All responses were seen in the group of 28 patients who had originally responded to TAM (18% of initial responders).
↵5-d DS = disease stabilization.
↵5-e Data adapted from Fig. 1 in Nomura et al., 1990.